 Adult Hemoglobinopathy Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
The adult hemoglobinopathy testing market is steadily expanding as healthcare systems worldwide intensify their focus on diagnosing and managing inherited blood disorders. Conditions such as sickle... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe adult hemoglobinopathy testing market is steadily expanding as healthcare systems worldwide intensify their focus on diagnosing and managing inherited blood disorders. Conditions such as sickle cell disease and various forms of thalassemia continue to present a substantial clinical burden, particularly among adult populations that may remain undiagnosed until later stages. Increasing awareness, combined with advancements in diagnostic technologies, is supporting the integration of hemoglobinopathy testing into routine healthcare practices. The market is projected to reach USD 2.3 billion in 2026 and is anticipated to grow to USD 3.3 billion by 2033, reflecting a compound annual growth rate of 5.30% over the forecast period.Market Insights The evolving landscape of hemoglobinopathy diagnostics is marked by the growing adoption of advanced and precise testing technologies. While conventional methods such as hemoglobin electrophoresis remain widely used, modern techniques including high-performance liquid chromatography and genetic testing are gaining strong traction due to their superior sensitivity and accuracy. These technologies enable the detection of a broader range of hemoglobin variants, supporting more effective clinical decision-making. The increasing integration of diagnostic testing into routine adult healthcare assessments is another important trend shaping the market. Healthcare providers are recognizing the importance of early identification, even in asymptomatic individuals, to prevent long-term complications. Furthermore, the availability of automated and high-throughput diagnostic platforms is improving laboratory efficiency and reducing turnaround times, thereby enhancing overall testing accessibility. In addition, the growing role of diagnostic laboratories and specialty clinics is contributing to the expansion of testing services. These facilities are investing in advanced technologies to meet rising demand and to deliver high-quality diagnostic outcomes. Drivers A key factor driving the growth of the adult hemoglobinopathy testing market is the rising prevalence of genetic blood disorders across the globe. Increased population mobility has led to a wider geographical distribution of these conditions, necessitating expanded screening programs in regions previously considered low-risk. This shift is significantly boosting the demand for adult diagnostic testing. Another major driver is the growing emphasis on early and accurate diagnosis. Identifying hemoglobinopathies at an early stage allows for timely intervention, better disease management, and improved patient outcomes. Healthcare authorities and organizations are actively promoting screening initiatives and awareness campaigns, further encouraging testing adoption. Technological progress continues to play a central role in market development. Innovations in molecular diagnostics and chromatography techniques are enabling more precise and reliable detection of hemoglobin variants. These advancements are not only improving diagnostic accuracy but also enhancing laboratory productivity. Additionally, the increasing focus on preventive healthcare is encouraging individuals to undergo routine health screenings, including tests for hereditary conditions. This trend is expected to sustain demand for hemoglobinopathy testing in adult populations. Business Opportunity The market presents a wide range of opportunities for stakeholders, particularly in the area of advanced diagnostic solutions. The growing acceptance of genetic testing is opening new avenues for innovation, as healthcare providers seek more comprehensive and personalized diagnostic tools. As the cost of genetic technologies continues to decline, their integration into standard testing protocols is expected to accelerate. Emerging economies offer significant potential for market expansion due to ongoing improvements in healthcare infrastructure and rising awareness levels. Countries across Asia Pacific, Latin America, and the Middle East are witnessing increasing investments in diagnostic capabilities, creating favorable conditions for market growth. The development of point-of-care testing solutions represents another promising opportunity. Portable diagnostic devices that deliver rapid results can significantly enhance accessibility, especially in remote and underserved areas. Companies focusing on user-friendly and cost-effective solutions are likely to gain a competitive edge. Strategic collaborations between diagnostic companies, healthcare providers, and research institutions are also shaping the market landscape. These partnerships are facilitating technological innovation, expanding distribution networks, and improving overall service delivery. Region Analysis North America remains a dominant region in the adult hemoglobinopathy testing market, supported by advanced healthcare infrastructure, high levels of awareness, and strong adoption of innovative diagnostic technologies. The presence of leading market players and continuous research activities further reinforce the region’s leadership. Europe holds a substantial share of the market, driven by well-established healthcare systems and government-supported screening programs. The increasing prevalence of hemoglobin disorders due to migration trends is also contributing to the demand for testing services in the region. Asia Pacific is expected to experience the fastest growth during the forecast period. The region has a high incidence of hemoglobinopathies, particularly in countries such as India and China. Rapid improvements in healthcare access, along with growing awareness and supportive government initiatives, are accelerating market expansion. Latin America and the Middle East and Africa are gradually emerging as important markets. Although challenges related to limited infrastructure persist, increasing investments and international collaborations are improving access to diagnostic services. These regions are expected to offer strong growth potential in the coming years. Key Players • Bio-Rad Laboratories, Inc. • Revvity, Inc. (formerly PerkinElmer) • Siemens Healthineers AG • Thermo Fisher Scientific Inc. • Trinity Biotech plc • F. Hoffmann-La Roche Ltd. • Danaher Corporation (Cepheid, Beckman Coulter) • Sysmex Corporation • QuidelOrtho Corporation • Quest Diagnostics Incorporated • ARUP Laboratories • Randox Laboratories Ltd. • BioMedomics Inc. • CapitalBio Technology Inc. • Chromsystems Instruments & Chemicals GmbH Segmentation By Test Type • Hemoglobin Electrophoresis • High-Performance Liquid Chromatography (HPLC) • Genetic Testing • Others By Indication • Sickle Cell Disease • Beta Thalassemia • Alpha Thalassemia By End-user • Hospitals • Diagnostics Laboratories • Specialty Clinics By Region • North America • Europe • Asia Pacific • Latin America • Middle East and Africa Table of Contents1. Executive Summary1.1. Global Adult Hemoglobinopathy Testing Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 3.1. Global Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 3.1.1. Hemoglobin Electrophoresis 3.1.2. High-Performance Liquid Chromatography (HPLC) 3.1.3. Genetic Testing 3.1.4. Others 3.2. Global Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 3.2.1. Sickle Cell Disease 3.2.2. Beta Thalassemia 3.2.3. Alpha Thalassemia 3.3. Global Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 3.3.1. Hospitals 3.3.2. Diagnostics Laboratories 3.3.3. Specialty Clinics 3.4. Global Adult Hemoglobinopathy Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 4.1. North America Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 4.1.1. Hemoglobin Electrophoresis 4.1.2. High-Performance Liquid Chromatography (HPLC) 4.1.3. Genetic Testing 4.1.4. Others 4.2. North America Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 4.2.1. Sickle Cell Disease 4.2.2. Beta Thalassemia 4.2.3. Alpha Thalassemia 4.3. North America Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 4.3.1. Hospitals 4.3.2. Diagnostics Laboratories 4.3.3. Specialty Clinics 4.4. North America Adult Hemoglobinopathy Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 4.4.2. U.S. Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 4.4.3. U.S. Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 4.4.4. Canada Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 4.4.5. Canada Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 4.4.6. Canada Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 5.1. Europe Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 5.1.1. Hemoglobin Electrophoresis 5.1.2. High-Performance Liquid Chromatography (HPLC) 5.1.3. Genetic Testing 5.1.4. Others 5.2. Europe Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 5.2.1. Sickle Cell Disease 5.2.2. Beta Thalassemia 5.2.3. Alpha Thalassemia 5.3. Europe Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 5.3.1. Hospitals 5.3.2. Diagnostics Laboratories 5.3.3. Specialty Clinics 5.4. Europe Adult Hemoglobinopathy Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.2. Germany Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.3. Germany Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.4. Italy Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.5. Italy Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.6. Italy Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.7. France Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.8. France Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.9. France Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.10. U.K. Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.11. U.K. Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.12. U.K. Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.13. Spain Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.14. Spain Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.15. Spain Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.16. Russia Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.17. Russia Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.18. Russia Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.4.19. Rest of Europe Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 5.4.20. Rest of Europe Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 5.4.21. Rest of Europe Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 6.1. Asia Pacific Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 6.1.1. Hemoglobin Electrophoresis 6.1.2. High-Performance Liquid Chromatography (HPLC) 6.1.3. Genetic Testing 6.1.4. Others 6.2. Asia Pacific Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 6.2.1. Sickle Cell Disease 6.2.2. Beta Thalassemia 6.2.3. Alpha Thalassemia 6.3. Asia Pacific Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 6.3.1. Hospitals 6.3.2. Diagnostics Laboratories 6.3.3. Specialty Clinics 6.4. Asia Pacific Adult Hemoglobinopathy Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.2. China Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.3. China Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.4.4. Japan Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.5. Japan Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.6. Japan Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.4.7. South Korea Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.8. South Korea Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.9. South Korea Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.4.10. India Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.11. India Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.12. India Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.4.13. Southeast Asia Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.14. Southeast Asia Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.15. Southeast Asia Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.4.16. Rest of SAO Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 6.4.17. Rest of SAO Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 6.4.18. Rest of SAO Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 7.1. Latin America Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 7.1.1. Hemoglobin Electrophoresis 7.1.2. High-Performance Liquid Chromatography (HPLC) 7.1.3. Genetic Testing 7.1.4. Others 7.2. Latin America Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 7.2.1. Sickle Cell Disease 7.2.2. Beta Thalassemia 7.2.3. Alpha Thalassemia 7.3. Latin America Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 7.3.1. Hospitals 7.3.2. Diagnostics Laboratories 7.3.3. Specialty Clinics 7.4. Latin America Adult Hemoglobinopathy Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 7.4.2. Brazil Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 7.4.3. Brazil Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 7.4.4. Mexico Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 7.4.5. Mexico Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 7.4.6. Mexico Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 7.4.7. Argentina Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 7.4.8. Argentina Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 7.4.9. Argentina Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 7.4.10. Rest of LATAM Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 7.4.11. Rest of LATAM Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 7.4.12. Rest of LATAM Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Adult Hemoglobinopathy Testing Market Outlook, 2020-2033 8.1. Middle East & Africa Adult Hemoglobinopathy Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033 8.1.1. Hemoglobin Electrophoresis 8.1.2. High-Performance Liquid Chromatography (HPLC) 8.1.3. Genetic Testing 8.1.4. Others 8.2. Middle East & Africa Adult Hemoglobinopathy Testing Market Outlook, by Indication, Value (US$ Bn), 2020-2033 8.2.1. Sickle Cell Disease 8.2.2. Beta Thalassemia 8.2.3. Alpha Thalassemia 8.3. Middle East & Africa Adult Hemoglobinopathy Testing Market Outlook, by End-user, Value (US$ Bn), 2020-2033 8.3.1. Hospitals 8.3.2. Diagnostics Laboratories 8.3.3. Specialty Clinics 8.4. Middle East & Africa Adult Hemoglobinopathy Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 8.4.2. GCC Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 8.4.3. GCC Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 8.4.4. South Africa Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 8.4.5. South Africa Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 8.4.6. South Africa Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 8.4.7. Egypt Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 8.4.8. Egypt Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 8.4.9. Egypt Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 8.4.10. Nigeria Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 8.4.11. Nigeria Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 8.4.12. Nigeria Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 8.4.13. Rest of Middle East Adult Hemoglobinopathy Testing Market Outlook, by Test Type, 2020-2033 8.4.14. Rest of Middle East Adult Hemoglobinopathy Testing Market Outlook, by Indication, 2020-2033 8.4.15. Rest of Middle East Adult Hemoglobinopathy Testing Market Outlook, by End-user, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Bio-Rad Laboratories, Inc. 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Revvity, Inc. (formerly PerkinElmer) 9.4.3. Siemens Healthineers AG 9.4.4. Thermo Fisher Scientific Inc. 9.4.5. Trinity Biotech plc 9.4.6. F. Hoffmann-La Roche Ltd. 9.4.7. Danaher Corporation (Cepheid, Beckman Coulter) 9.4.8. Sysmex Corporation 9.4.9. QuidelOrtho Corporation 9.4.10. Quest Diagnostics Incorporated 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（landscape）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
